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The degeneration of cholinergic neurons of the nucleus basalis of Meynert (NBM)
in the basal forebrain (BF) is associated to the cognitive decline of Alzheimer’s
disease (AD) patients. To date no resolutive therapies exist. Cell-based replacement
therapy is a strategy currently under consideration, although the mechanisms
underlying the generation of stem cell-derived NBM cholinergic neurons able of
functional integration remain to be clarified. Since fetal brain is an optimal source
of neuronal cells committed towards a specific phenotype, this study is aimed at
isolating cholinergic neurons from the human fetal NBM (hfNBMs) in order to study
their phenotypic, maturational and functional properties. Extensive characterization
confirmed the cholinergic identity of hfNBMs, including positivity for specific markers
(such as choline acetyltransferase) and acetylcholine (Ach) release. Electrophysiological
measurements provided the functional validation of hfNBM cells, which exhibited
the activation of peculiar sodium (INa) and potassium (IK) currents, as well as the
presence of functional cholinergic receptors. Accordingly, hfNBMs express both
nicotinic and muscarinic receptors, which were activated by Ach. The hfNBMs
cholinergic phenotype was regulated by the nerve growth factor (NGF), through
the activation of the high-affinity NGF receptor TrkA, as well as by 17-β-estradiol
through a peculiar recruitment of its own receptors. When intravenously administered
in NBM-lesioned rats, hfNBMs determined a significant improvement in memory
functions. Histological examination of brain sections showed that hfNBMs (labeled
with PKH26 fluorescent dye prior to administration) reached the damaged brain areas.
Frontiers in Cellular Neuroscience | www.frontiersin.org 1 October 2017 | Volume 11 | Article 339
Morelli et al. Human Basal Forebrain Cholinergic Neurons
The study provides a useful model to study the ontogenetic mechanisms regulating the
development and maintenance of the human brain cholinergic system and to assess new
lines of research, including disease modeling, drug discovery and cell-based therapy
for AD.
Keywords: nucleus basalis of Meynert, cell-based therapy, NGF, estrogen receptors, primary cilium, cholinergic
receptors
INTRODUCTION
The basal forebrain (BF) region is a broad topographic
term describing a heterogeneous set of cellular structures
on the medial and ventral cerebral hemisphere. It comprises
the nucleus basalis of Meynert (NBM), the vertical and
horizontal diagonal bands of Broca and the medial septal
nucleus (Mesulam, 2013). This complex region contains
magnocellular neurons that provide the major cholinergic
projections to the cerebral cortex, hippocampus and amygdala.
The BF cholinergic system has been implicated in the
modulation of an ever-expanding set of behavioral states,
including attention, memory and learning (Ferreira-Vieira et al.,
2016). Importantly, the degeneration and loss of cholinergic
neurons within the BF, especially in the NBM, represents
a pathological correlate of the well-documented cholinergic
derangement in Alzheimer’s disease (AD) patients (Kilimann
et al., 2014).
Despite its implications as pathological substrate for
cholinergic deficiency in AD brain, very little is known
about the developmental properties of the NBM neuronal
contingent during embryogenesis. As we move towards an
era of stem cell-based treatments for several pathologies,
including neurodegenerative disorders, the use of cholinergic
cell-based transplantation approaches to treat AD should be
considered. However, extensive studies are needed to identify the
mechanisms underlying the generation of functionally integrated
stem cell-derived NBM cholinergic neurons. Since fetal brain
is an optimal resource to study developmental processes of
neurons already committed towards a specific phenotype, the
aim of the present study is the isolation and characterization of
human cholinergic neurons from the fetal NBM.
Studies in animal models after fetal tissue transplantation
have demonstrated that neuronal replacement and partial
reconstruction of damaged neuronal circuitry is possible
(Björklund and Lindvall, 2000). There is also evidence from
clinical trials that fetal graft in the diseased human brain
can lead to symptomatic relief (Paganini et al., 2014).
Human neurological disorders such as AD, Parkinson’s disease
(PD), Huntington’s disease, stroke or spinal cord injury
are caused by the loss of neurons and glial cells in the
brain or spinal cord. In each of them a different spectrum
of cell types is affected; therefore, before clinical trials
are initiated, we need to know much more about how
to control cell proliferation and differentiation into specific
phenotypes, promote their integration into existing neural
and synaptic circuits, and determine functional recovery in
animal models closely resembling the human disease. Recently,
Grealish et al. (2014) have provided preclinical evidence that
the potency of the human embryonic stem cell-derived
dopaminergic neurons, with respect to functional efficacy
and long-distance targeted reinnervation, is comparable to
that of fetal ventral mesencephalon cells, which provides
important support for their therapeutic potential and use for cell
replacement therapy in PD patients.
The NBM precursor neurons were reported to originate in
the telencephalic subpallium (Xu et al., 2008). A new pallial
origin of these neurons has been also described (Pombero et al.,
2011). These differences in the BF cholinergic system ontogenesis
might explain their different connection patterns (cortex vs.
hippocampus) and functions in cognitive processes, as well as
their specific responses to pathological stimuli. The data on
the development and anatomical organization of the NBM in
the human fetal brain revealed early maturation. The earliest
signs of the acetylcholinesterase (AchE) activity, indicative of
acetylcholine (Ach) release, appear as early as 9 weeks of gestation
(w.g.) in the area where the prospective basal nucleus develops
and the first AChE-reactive bundles form between this age
and 10.5 w.g. (Kostovi´c, 1986). At 12–15 weeks, the positive
cell group appear and the basal nucleus can be separated into
several subdivisions. Innervation of the developing cortex and
subcortical areas by AchE-reactive fibers occurs between 16 w.g.
and 28 w.g. An overall high degree of structural and chemical
complexity is early achieved in the NBM of human fetal brain
(Kracˇun and Rösner, 1986), suggesting that this brain area plays
an important role in the earliest cortical connections due to its
specific functional entity. Of great importance for the definition
of the NBM within the human brain was the demonstration that
this nucleus increases both in its relative and absolute size and
differentiation with increasing cerebralization (Gorry, 1963).
In this work, we isolated neurons from NBM of 12 week old
human fetuses, which is the proper time during embryogenesis
when the commitment into differentiation programs for BF
nuclear complex is well defined (Kostovi´c, 1986). Although
retaining growth and differentiation potentials, an extensive
phenotypical and functional characterization demonstrated that,
in the chosen ‘‘developmental window’’, these neurons possess
a clear BF cholinergic identity, which may be importantly
induced and maintained by physiological factors, such as
nerve growth factor (NGF) and estrogens. More importantly,
when intravenously injected into NBM-lesioned rats these cells
reached the damaged brain area and ameliorated cognitive
deficiencies typical of AD. These results provide the first
characterization of human fetal BF cholinergic neurons and
show their potential as a useful resource in the research field of
cognitive disorders.
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MATERIALS AND METHODS
Further information can be found in Supplementary Material.
Cell Culture
The use of human fetal tissue for research purposes was approved
by the National Ethics Committee and the local ethic committee
for investigation in Humans of the University of Florence (Permit
Number: 678304). Human fetuses biopsies were obtained from
therapeutic medical abortions after women approved and signed
the informed consent document, as already reported (Gallina
et al., 2008). NBM tissue was dissected from two female 12-weeks
old human fetuses and incubated with 1 mg/ml collagenase
type IV (Sigma-Aldrich Corp., St. Louis, MO, USA). The
cell suspensions were mechanically dispersed by pipetting and
cultured in Coon’s modified Ham’s F12 medium (Euroclone,
Milan, Italy) supplemented with 10% FBS (Hyclone, Logan, UT,
USA). Cells were used within the 26th passage.
Quantitative Real-Time RT-PCR
Isolation of total RNA and cDNA synthesis were performed
using the ‘‘RNeasy Micro kit’’ (Qiagen, Hilden, Germany) and the
iScriptTM cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules,
CA, USA). For some genes, quantitative real time PCR (qRT-
PCR) was performed according to the fluorescent TaqMan
methodology, as previously described (Morelli et al., 2008)
Primers and probes for the target genes were predeveloped
assays (Life Technologies, Carlsbad, CA, USA) as listed in
Supplementary Table S1. For the remaining genes, qRT-PCR
was performed using SsoFastTM EvaGreenr Supermix (Bio-
Rad Laboratories) as previously described (Morelli et al.,
2013). Specific primers sequences for the target genes are
reported in Supplementary Table S2. The 18S ribosomal RNA
subunit was chosen as the housekeeping gene for relative
quantification. Data analysis was based on the comparative
threshold cycle (Ct) using the 2−∆∆Ct method and carried out
with the MyIQ2TM Two-Color Real-Time PCR Detection System
(Bio-Rad Laboratories).
Immunofluorescence
The analysis was performed as previously described (Sarchielli
et al., 2014) using the following primary antibodies: anti-ChAT
polyclonal antibody (pAb; 1:200; Millipore, Temecula, CA,
USA), anti-VAchT pAb (1:1000), anti-acetylated α-tubulin
mAb (1:500) from Sigma-Aldrich Corp., St. Louis, MO, USA;
anti-GFAP monoclonal antibody (mAb; 1:100), anti-α tubulin
mAb (1:2000), anti-ERα mAb (1:50), anti-ERβ mAb (1:50) from
Santa Cruz Biotechnology (Santa Cruz, CA, USA); anti-GPR30
pAb (1:40, Abcam, Cambridge, UK), followed by Alexa Fluor
488 or 568 goat anti-rabbit or Alexa Fluor 488 goat anti-mouse
(1:200, Molecular Probes, Eugene, Oregon), as appropriate. For
α-tubulin and acetylated α-tubulin staining, cells were cultured
in serum/phenol red-free condition and treated with NGF
(100 ng/ml), E2 (10 nM) or G1 (100 nM) for 24/48 h in
presence or absence of the receptor inhibitors K252a (200 nM),
Tamoxifen (100 nM) or G15 (1 µM), respectively. The number
of cells with neurites longer than four times the cell body
(α-tubulin staining) or the number of ciliated cells (acetylated
α-tubulin staining) was calculated by counting the stained cells
in ten fields per slide of three different experiments performed in
triplicate.
Flow Cytometry
As previously described (Sarchielli et al., 2017), after fixation and
permeabilization, cells were resuspended in PBS with 1% FBS
and incubated with the following primary antibodies: anti-O4
mAb (1:100), anti-MAP2 pAb (1:100), anti-ChAT pAb (1:100)
from Millipore; anti-GFAP mAb (1:100), anti-TrkA pAb (1:100)
from Santa Cruz Biotechnology, followed by incubation with
Alexa Fluor 488 goat anti-mouse IgM (1:200), Alexa Fluor
568 goat anti-rabbit or Alexa Fluor 488 goat anti-mouse IgG
(H + L; 1:200) secondary antibodies from Molecular Probes, as
appropriate. Cells were analyzed on a FACSCanto II instrument
(BD Pharmingen, San Diego, CA, USA) using BD FACSDiva
(BD) and FlowJo v10 (Tree Star, Inc., Ashland, OR, USA)
softwares.
Acetylcholine Release Assay
Cells were cultured in choline chloride free medium (Sigma-
Aldrich Corp., St. Louis, MO, USA) until subconfluence, then
the Ach release in the culture medium was quantified by
Choline/Acetylcholine Assay Kit (Abcam), according to the
manufacturer’s instructions and using a FlexStation 3 Microplate
Reader (Molecular Devices, Sunnyvale, CA, USA).
Western Blot Analysis
Cells were cultured in serum/phenol red-free condition and
treated with NGF (10–100 ng/ml), E2 (10−10–10−7 M) or G1
(100 nM) in presence or absence of the receptor inhibitors
K252a (200 nM), Tamoxifen (100 nM) or G15 (1 µM).
Protein extracts (20 µg) were subjected to immunoblotting as
previously described (Sarchielli et al., 2014) using the following
primary antibodies: anti-p-TrkA pAb (1:1000), anti-pERK
1/2 mAb (1:1000) from Cell Signaling Technologies (Danvers,
MA, USA); anti-p-CREB pAb (1:1000), anti-α-tubulin mAb
(1:2000), anti-β actin mAb (1:10000), anti-GAP43 mAb (1:1000),
anti-STAT1 pAb (1:1000) from Santa Cruz Biotechnology;
anti-c fos pAb (1:1000, Sigma-Aldrich); anti-ChAT pAb (1:2000,
Millipore).
Electrophysiology
Whole-cell patch-clamp recordings were performed in −60 mV
clamped-cells by using the following solutions: extracellular
(mM): HEPES 10, D-glucose 5, NaCl 140, KCl 3, MgCl2
2, and CaCl2 2 (pH 7.4). Pipette (mM): K-Aspartate 130,
MgCl2 2, Na2-ATP 5, Na2-GTP 0.1, EGTA 11, HEPES 10
(pH 7.2). Data were acquired with an Axopatch 200B amplifier
(Axon Instruments, Union City, CA, USA), low-pass filtered
at 10 kHz, stored and analyzed with a pClamp 9.2 software
(Axon Instruments). Detailed protocols used to evoke voltage-
dependent K+ or Na+ currents are described in Supplementary
Material. Drugs used were applied by superfusion with a
three-way perfusion valve controller (Harvard Apparatus).
Current-clamp recordings were performed by applying 12 steps
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of current injection (300 ms duration; 100 pA increment, from
−100 pA to 1000 pA) from the resting membrane potential of
the investigated cell, as already described (Coppi et al., 2012) and
detailed in Supplementary Material.
Radioligand Binding Assays
Cell membrane preparations (0.5–0.7 mg/ml) were used for
saturation binding assay with [3H]NMS (0.05–1.6 nM; Perkin-
Elmer Life and Analytical Science), or competition binding
assay (0.2 nM) with the muscarinic antagonist metoctramine
(0.1 nM–0.1 mM; Sigma-Aldrich) as previously described
(Matucci et al., 2016). Nonspecific binding was defined using
10 µM Atropine (Sigma-Aldrich).
Cell Proliferation Assay
Cell proliferation was determined by MTT assay (Sigma-Aldrich
Corp., St. Louis, MO, USA) as previously described (Ambrosini
et al., 2015). Cell viability was expressed as relative percentage of
viable cells over control, taken as 100% (mean± SEM) from three
separate experiments performed in quadruplicate.
In Vivo Study
Animals
All animal procedures were carried out according to the EC
Directive 86/609/EEC for animal experiments and National
guidelines for animal care with the approval of Italian Ministry
of Health (Permit Number: 567/2015-PR). Three-month-old,
230–250 g male Wistar rats (Harlan, Milan, Italy) were used.
Either saline (0.9%) or quisqualic acid (QA; 0.12 M) were injected
into the right NBM at the following stereotactic coordinates:
AP = −0.2; L = −2.8 and H = 6.8 from Bregma (Paxinos
and Watson, 2006) in anesthetized rats. The animals were
equally divided into four groups (n = 5–6 per group): Group
I, QA-injected and subjected to intravenous administration
of human fetal NBM cells (hfNBMs; 1.5 × 106 in 300 µl
PBS) by the tail vein; Group II, QA-injected; Group III,
saline-injected and subjected to intravenous administration of
hfNBMs (1.5 × 106 in 300 µl PBS); Group IV, un-injected
rats (controls). One day prior the intravenous administration
of cells and for all the length of the experiment rats were
treated with Cyclosporine (2 mg/kg/day). Before administration,
the cells were labeled with the PKH26 Red Fluorescent dye
(Sigma-Aldrich Corp., St. Louis, MO, USA) according to the
manufacturer’s instructions. Rats from group I were sacrificed
on day 1, 7 and 21 after hfNBMs administration. Rats from the
other groups were sacrificed on day 21. Anesthetized (chloral
hydrate, 400 mg/kg i.p.) rats were perfused transcardially with
0.9% saline followed by 4% paraformaldehyde and brains were
paraffin embedded. Livers from rats subjected to intravenous
administration of hfNBMs were harvested and analyzed to
detect the presence of PKH26 labeled cells in systemic
organs.
Immunohistochemistry
Immunohistochemical analyses of rat brains were performed
on 5.0 µm coronal paraffin-embedded sections. Anti-GFAP
(1:1000; Agilent Technologies, Santa Clara, CA, USA)
and anti-ChAT (1:200; Millipore) pAbs were used to
detect astrocytes and cholinergic neurons, respectively.
ChAT-positive cells in the NBM were counted under a
10× objective. Five sections per animal, anteroposterior
standardized with respect to the injection site and spaced
50–100 µm from one another, were analyzed. The total
number of ChAT-positive cells in the QA-injected NBM
was averaged, expressed as a percentage of that counted in
the saline-injected NBM (n = 3 per group), and analyzed
using Prism 5.0 (GraphPad Software, San Diego, CA,
USA).
Morris Water Maze Test
During the third week after hfNBMs administration rats
were tested in the Morris Water Maze (MWM). The MWM
apparatus consisted of a circular pool (1.6 m in diameter
and 0.36 m high) made of green plastic. The pool was
filled to a depth of 20 cm with water (24–25◦C) that was
made dark by the addition of non-toxic dark paint. Rats
were tested in the reference memory version of MWM with
the procedure previously described for mice (Grossi et al.,
2013).
Step-Down Inhibitory Avoidance Task
The day after the end of MWM task the animals were tested in
the Step-Down inhibitory avoidance task as previously described
for mouse (Grossi et al., 2009) with some modifications. The
apparatus was an open field plexiglas box (50 × 25 × 25 cm)
with a steel rod floor and a plexiglas platform (5 × 8 × 25 cm)
set on the grid floor to which intermittent electric shocks were
delivered.
Statistics
Data are expressed as mean± SEM. Student’s paired or unpaired
t-tests or One- and two-way analysis of variance (ANOVA)
followed by Newman–Keuls or Bonferroni post-test analysis
were performed, as appropriate, in order to determine statistical
significance (set at p < 0.05). Data were analyzed using software
package GraphPad Prism (GraphPad Software).
RESULTS
Phenotypic Characterization of hfNBMs
In order to isolate human cholinergic neurons from NBM,
we dissected and dissociated the corresponding region within
the BF of 12-week old human fetuses. The cell suspensions
obtained were plated and maintained in Coon’s medium
supplemented with fetal bovine serum. One week after
plating, the cells started to emerge from aggregates and
grew as a monolayer population of adherent cells. At this
stage, the cells were harvested and replated into fresh
medium generating a primary cell culture of hfNBMs neurons
(Figure 1A) that was propagated and characterized at different
passages.
In order to define the identity of the hfNBM population, we
analyzed the expression of immature and mature neural lineage
cell markers by qRT-PCR, immunofluorescence analysis and
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FIGURE 1 | Gene expression profile and phenotypic characterization of hfNBMs. (A) Phase contrast microphotographs showing cell morphology at passage 4 (scale
bar 50 µm). (B,C) Relative mRNA expression by quantitative real time-PCR (qRT-PCR) analysis of target genes normalized over 18S ribosomal RNA subunit, taken
as the reference gene; data are mean ± SEM (n = 6). (D) Representative images of cells expressing ChAT, VAchT and GFAP (DAPI counterstained nuclei, scale bar
50 µm). (E) Flow cytometric analysis for O4, GFAP, MAP2, ChAT e TrkA proteins; the bar graph shows the percentage of positive cells reported as mean ± SEM
(n = 4).
flow cytometry. As shown in Figure 1B, hfNBMs expressed high
abundance of both nestin and β-tubulin III transcripts, which are
indicative of neural precursors committed toward the neuronal
lineage. Accordingly, we found that the mRNA expression
of MAP2, a neuronal marker, was more abundant than the
markers of either astroglial (glial fibrillary acidic protein, GFAP)
or oligodendroglial (OLIG2) lineages. In addition, hfNBMs
expressed a panel of specific genes for NBM cholinergic identity,
such as those codifying for enzymes essential for Ach synthesis
(choline acetyltransferase, CHAT) and degradation (ACHE),
the Ach vescicular transporter (VACHT), the calcium binding
protein calbindin 1 (CALB1), and both types of the NGF
receptors (TRKA, CD271; Figure 1C). This gene expression
profile was retained by cells throughout the different passages in
culture (p. 4–p.26).
Immunocytochemical analysis performed in hfNBMs
confirmed the prominent neuronal phenotype with a strong
immunopositivity to ChAT and VAchT protein expression
and a rare detection of GFAP-positive cells (Figure 1D).
To provide a quantitative characterization of the hfNBMs
phenotype, we used flow cytometry. As shown in Figure 1E, the
majority of cells was positive for MAP2 (97.25 ± 2.75%), ChAT
(97.03 ± 2.09%) and TrkA (92.45 ± 5.65%), with a very low
percentage of cells being positive for glial markers, such as GFAP
(1.65 ± 0.05%) and O4 (4.05 ± 2.55%). Finally, the cholinergic
phenotype of hfNBM cells was confirmed by the detection
of basal release of Ach (1.23 ± 0.76 nmol/ml) in the culture
medium.
Functional Characterization of hfNBM
Cells
We next profiled the functional features of hfNBMs by
studying their electrophysiological properties. The present
results have been obtained by patch-clamp whole cell
recordings from 102 cells (from p14 to p26). The registered
electrophysiological parameters, including resting membrane
potential (Vm), membrane resistance (Rm) and membrane
capacitance (Cm), showed values typically found in neurons,
as reported in Table 1. More relevantly, 89% of hfNBMs
tested (91 out of 102) exhibited fast inward currents in
response to a step depolarization (Figure 2A), indicating the
expression of functional voltage-gated Na+ channels (Table 1).
These currents were rapidly activating and inactivating,
tetrodotoxin (TTX)-sensitive, and presented an I–V plot
TABLE 1 | Electrophysiological properties of hfNBMs.
Membrane potential (Vm; mV) −44.8 ± 3.2 (n = 102)
Membrane resistance (Rm; MΩ) 749.7 ± 77.7 (n = 102)
Membrane capacitance (Cm; pF) 30.1 ± 2.1 (n = 102)
Sodium current (INa) amplitude at 0 mV (pA) −993.8 ± 72.4 (n = 91)
K+ current (IK) amplitude at +80 mV (pA) 556.4 ± 50.7 (n = 102)
Data are presented as mean ± SEM of n cells.
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FIGURE 2 | Electrophysiological characterization of hfNBMs. (A) Original Na+ currents (INa) recorded by whole-cell patch clamp technique in a representative cell (at
p19). Calibration: 200 pA, 5 ms. (B) Current to voltage relationship (I–V plot) of INa recorded in the same cell in absence (•) or in presence (◦) of 1 µM tetrodotoxin
(TTX). (C) Activation (•) and inactivation (◦) curves of INa evoked in the same cell. Black lines represent fittings with Boltzmann equations (V1/2
activation = −14.73 ± 1.44 mV; slope = 4.12 ± 0.38; V1/2 inactivation = −56.25 ± 3.60 mV; slope = 5.85 ± 4.10). (D) Original whole-cell current-clamp recordings
in a cell at p19 showing a resting membrane potential of −48 mV. A prominent sag is observed at −100 pA of current injection. Note that +800 pA current injection
elicited a single, small amplitude, action potential (gray trace). No repetitive firing activity was elicited at higher values of current injection (+900 pA; +1 nA). Scal bars:
100 ms; 20 mV. (E) Original current traces elicited by a depolarizing voltage step protocol in a representative cell (at p16) expressing only delayed rectifier (IK) currents
(left panel) or in a different cell (at p26) expressing either IK or transient IA currents (right panel). Calibration: 500 pA, 50 ms. (F) Original Kir current traces elicited by a
hyperpolarizing voltage step protocol in a representative cell (at p17). Calibration: 200 pA, 25 ms. (G,H) Original current traces (G) and pooled data (H, left panel)
recorded in −60 mV clamped cell where nicotine (Nic, 10 µM) activated an inward current blocked by the selective antagonist Mecamilamine (MCM, 10 µM). Scale
bars: 100 pA, 1 min. Right panel: pooled data indicating that, concomitantly with inward current activation, Nic also concentration-dependently depolarized Vm
(∗p < 0.05, n = 12). (I) Concentration-response curve of Nic (EC50 = 2.6 µM, C.L. 2.05–3.4 µM) in hfNBMs. (J) Pooled data indicating the concentration-dependent
effect of Nic, alone or in combination (10 µM Nic) with MCM, on inward current and Rm in hfNBMs. ∗p < 0.05 vs. 0.1 µM Nic; §p < 0.05 vs. 10 µM Nic. Data are
expressed as mean ± SEM from at least n = 4. (K) Relative mRNA expression by qRT-PCR analysis of nicotinic receptor subunits normalized over 18S ribosomal
RNA subunit, taken as the reference gene, and reported as mean ± SEM (n = 6).
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and an activation-inactivation curve (activation curve:
V1/2 = −14.7 ± 1.4 mV; slope factor = 4.2 ± 0.4; inactivation
curve: V1/2 = −21.7 ± 6.2; slope factor = 3.7 ± 0.2) typical of
Na+ currents (INa) recorded in neurons (Figures 2B,C), thus
providing functional validation of the neuronal profile of the
hfNBMs.
In order to elucidate hfNBM firing activity cells presenting INa
currents were investigated under current-clamp configuration.
A prominent sag was observed upon negative current injection
(−100 pA, Figure 2D) in the majority of cells investigated
(see Table 2). A single, small amplitude, action potential
(AP) was elicited in some cells upon depolarizing current
injections (from +500 pA). A modest fast AHP (fAHP)
followed the single AP. Repetitive firing was never observed,
nor slow AHP (sAHP) at the end of the current step.
Quantitative analysis of current-clamp parameters is reported in
Table 2.
Concerning investigation of K+ currents, we applied a
voltage step protocol (Figure 2E, inset) able to activate both
slowly activating and not inactivating (delayed rectifier) K+
currents (IK: Figure 2E, left panel) or fast activating and
rapidly inactivating K+ currents (IA: Figure 2E, right panel), in
accordance to Sah (1995). Contrarily to IA currents, detected only
in a minority of hfNBMs (37.2%; 38 out of 102), IK currents were
observed in all cells tested. We also applied a specific voltage
protocol (Figure 2F, inset) to activate inwardly rectifying K+
currents (Kir), which were recorded in about 40% of cells (43 out
of 102; Figure 2F). All these currents (IK, IA and Kir) were
abolished when extra- and intracellular K+ ions were replaced
by equimolar Cs+ (not shown), thus confirming that they are
potassium currents.
We further examined the presence of functional cholinergic
(nicotinic and muscarinic) receptors in hfNBMs. First, we
investigated the expression of potential nicotinic receptors by
applying the selective agonist nicotine (Nic). When a single
hfNBM cell was voltage clamped at −60 mV, Nic (10 µM,
2 min application) evoked an inward current (Figure 2G, left
panel) completely inhibited by the selective Nic antagonist
mecamilamine (MCM, 10 µM, Figure 2G, right panel and
Figure 2H, left panel; p < 0.05). The effect of Nic was
observed in 76.3% of tested cells (29 out of 38 cells) and
was concentration-dependent (Figure 2J, left panel) with
EC50 = 2.6 µM (confidential limits: 2.05–3.4 µM; Figure 2I).
Concomitantly with inward current activation, Nic also induced
a MCM-sensitive depolarization of Vm (Figure 2H, right panel)
and a concentration-dependent decrease in Rm (Figure 2J, right
panel).
To explore the functional effects of muscarinic receptors, we
applied Ach or carbachol (Cch). A depolarizing voltage-ramp
protocol was used to elicit a wide range of overall voltage-
dependent currents in hfNBMs before, during and after Ach
or Cch application. Depolarizing voltage ramps in hfNBMs
evoked a majority of K+ currents plus a mixture of other
voltage-gated currents as indicated by their reversal potential
of about −45 mV (Figure 3A: black trace), which does not
coincide with the predicted K+ equilibrium potential in our
experimental conditions (EK = −95.2 mV). However, the most
of ramp currents are K+ currents since they are almost absent
in Cs+-replacement experiments (Supplementary Figure S1A).
Figure 3A shows a typical experiment where Ach (10 µM)
reversibly increased ramp-evoked K+ currents in a single cell.
The Ach-sensitive current is an outward current with an
activation voltage around −40 mV (Figure 3B). Ach-induced
current increase was concentration-dependent (Figure 3C;
p < 0.01), prevented by Cs+ replacement (Supplementary
Figure S1B) and blocked by the muscarinic antagonist atropine
(ATR, 100 nM, Figure 3C; p < 0.05). The maximal effect of
Ach was elicited at a concentration of 10 µM with a ‘‘bell-
shaped’’ curve observed at higher concentrations, probably due
to higher rate of Ach degradation by AchE, which is expressed
by hfNBMs. Cch mimicked Ach effects on ramp-evoked currents
as it concentration-dependently increased outward K+ currents
(Figure 3D). Finally, either Ach or Cch induced an ATR-sensitive
Vm hyperpolarization (Figure 3E; p < 0.001) in line with K+
channel opening. Figures 3F,G show Ach- and Cch-sensitive
currents in the absence or presence of ATR, respectively.
When tested on the voltage-step protocol to specifically activate
K+ currents, either Ach (Figure 3K) or Cch (Figure 3M)
increased currents with kinetic properties and I-V plot typical
of delayed rectifier IK conductances (Figures 3K,L, left panels;
Figures 3M,N, left panel); both effects were blocked by ATR
(Figures 3L,N, right panels). Thus, we conclude that muscarinic
receptor activation in hfNBMs by Ach or Cch enhances delayed
rectifier IK currents.
It should be mentioned that, when Ach was applied in the
presence of ATR, we observed a transient increase in the inward
component of ramp-evoked currents (Figure 3H). This effect,
observed only in a subset of hfNBMs (4 out of 7), peaked
within the first minute of application and rapidly disappeared
before agonist washout (Figure 3H, inset). The reversal potential
of Ach-sensitive current recorded in the presence of ATR was
around 0 mV (Figure 3I), coherently with the activation of
rapidly desensitizing, non-selective cation channels, such as
nicotinic receptors.
In order to define which types of cholinergic receptors were
expressed by hfNBMs, we analyzed the mRNA expression of the
different neuronal subunits of nicotinic receptors (from α2 to
α7 and from β2 to β4) along with the different subtypes of
TABLE 2 | Quantitative analysis of current-clamp parameters recorded in hfNBMs.
Passage in culture (p) n. cells with AP n. cells with SAG Sag ratio AP threshold (mV) AP amplitude (mV) AP half width (ms) fAHP (mV)
p15 (n = 12) n = 4 n = 10 2.9 ± 0.2 −32.2 ± 1.6 21.8 ± 2.0 1.95 ± 0.1 8.01 ± 3.3
p19 (n = 13) n = 3 n = 13 3.1 ± 0.4 −41.1 ± 2.1 25.5 ± 4.6 1.06 ± 0.3 9.3 ± 3.3
Data are presented as mean ± SEM of n cells.
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FIGURE 3 | Muscarinic receptor activation by acetylcholine (Ach) or carbachol increases outward K+ currents in hfNBMs. (A) Original patch clamp current traces
recorded in a representative cell where a voltage ramp protocol (−120/+80 mV, 800 ms) was applied before (ctrl), during and after (wash) 10 µM Ach application.
Inset: time course of ramp-evoked currents at +80 mV (open circles) or at −120 mV (open diamonds) in the same cell. (B) Net Ach-sensitive current, obtained by
subtraction of the control ramp from that recorded in Ach, in the same cell. (C–E) Pooled data of Ach (C) and Carbachol (Cch, D) concentration-dependent effects
on ramp current measured at +80 mV and on membrane potential (Vm, E). All these effects induced by muscarinic agonists are blocked by 100 nM atropine (ATR)
(C,D) ∗p < 0.05; ∗∗p < 0.01, ∗∗∗p < 0.001 vs. 0.1 µM Ach; §p < 0.05 vs. 10 µM Ach, One-way analysis of variance (ANOVA), Newman-Keuls post test. Number of
cells tested is reported in parenthesis. (E) ∗∗∗p < 0.001 vs. respective ctrl, paired Student’s t-test, n = 12 Ach alone; n = 8 Ach + ATR; n = 6 Cch alone; n = 4 Cch +
ATR. (F) Averaged Ach-sensitive currents recorded in the absence (filled circles; n = 12) or in the presence (open circles; n = 10) of 100 nM ATR. (G) Averaged
Cch-sensitive currents recorded in the absence (filled circles; n = 6) or in the presence (open circles; n = 5) of 100 nM ATR. (H) Original current traces evoked by a
voltage ramp protocol in a representative cell in the presence of ATR immediately before (black trace: ctrl) or during (1 min: gray trace; 4 min: dotted gray trace)
10 µM Ach application. Inset: Time course of ramp-evoked current at +80 mV (open circles) or −120 mV (open diamonds) in the same cell. Note the “nicotinic-like”
effect of Ach revealed in the presence of ATR. (I) Averaged net Ach-sensitive current, obtained by subtraction of the control ramp from the Ach trace, recorded in the
presence of 100 nM ATR in five cells investigated. (J) Relative mRNA expression by qRT-PCR analysis of muscarinic receptor subunits normalized over 18S
ribosomal RNA subunit, taken as the reference gene, and reported as mean ± SEM (n = 6). (K) Left panel: original current traces evoked by a voltage step protocol
(from −40 to +80 mV, 10 mV steps, 200 ms duration, pre-step = −80 mV) in a representative hfNBM cell before (black trace) or during (gray trace) Ach (10 µM)
application. Right panel: net Ach-activated current, obtained by subtraction of the control ramp from the Ach trace, in the same cell. (L) Averaged I–V plots of
step-evoked currents recorded in Ach alone (10 µM, n = 8, left panel) or in the presence of ATR (100 nM, n = 3, right panel). ∗p < 0.05; ∗∗p < 0.01 vs. ctrl; paired
Student’s t-test. (M) Left panel: original current traces evoked by a voltage step protocol in a representative cell before (black trace) or during (gray trace) Cch
(50 µM) application. Right panel: net Ach-activated current, obtained by subtraction of the control ramp from the Cch trace, in the same cell. (N) Averaged I–V plots
of step-evoked currents recorded in Cch alone (50 µM, n = 4, left panel) or in the presence of ATR (100 nM, n = 3, right panel). ∗p < 0.05; ∗∗p < 0.01 vs. ctrl.
muscarinic receptors (from M1 to M5). As shown in Figure 2K,
hfNBMs expressed all the nicotinic receptor subunits analyzed,
even though at different levels, with α5 subunit (CHRNA5)
being the most abundant and β3 subunit (CHRNB3) the less
expressed (Figure 2K). Similarly, the expression of all the
muscarinic receptor isoforms was detected (Figure 3J). In
particular, we found high levels of the M2 (CHRM2) and
M3 (CHRM3) subtypes. It is known that the M2 isoform is
particularly important for cholinergic neuron function as it acts
as a pre-synaptic autoreceptor mediating an inhibitory action
on Ach release. Hence, the presence of muscarinic receptors,
and in particular M2 sites, in hfNBMs was further investigated
by radioligand binding analysis. Saturation curves obtained
at equilibrium conditions with the non-selective muscarinic
antagonist [3H]-NMS resulted in a maximum binding capacity
(Bmax) of 83.52 ± 18.72 fmol/mg protein and in a dissociation
constant (KD) of 0.07 ± 0.01 nM, thus indicating the
presence of high affinity muscarinic cholinergic receptor binding
sites (Supplementary Figure S2A). To detect the presence of
M2 sites we performed competition binding experiments, using
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FIGURE 4 | NGF/TrkA signaling activation and effects of NGF on hfNBMs. (A–D) Immunoblotting of TrkA, ERK 1/2 and CREB phosphorylation and c-fos expression
induced by 100 ng/ml NGF for 3, 15, 30 min (min) or 3.5 h in presence or absence of the receptor inhibitor K252a (200 nM); band intensity was normalized over
α-tubulin signal and expressed as % of untreated cells; data are mean ± SEM (∗p < 0.05 vs. untreated cells, #p < 0.05 vs. NGF, n = 3). (E) MTT assay of hfNBMs
untreated or treated with 10–100 ng/ml NGF for 24 h; data are expressed as percentage of untreated cells and are mean ± SEM (§§p < 0.005 vs. untreated cells,
++p < 0.005 vs. NGF, n = 3). (F) Neurite outgrowth analysis by α-tubulin staining of hfNBMs treated or not with 100 ng/ml NGF for 24 or 48 h in presence or
absence of K252a (200 nM); the graph shows the percentage of cells with neurites longer than four times the cell body, calculated by counting 10 fields per slide of
three separate experiments (◦◦p < 0.001 vs. CTL, ##p < 0.001 vs. NGF; DAPI counterstained nuclei, scale bar 100 µm). (G) Acetylated α-tubulin staining of primary
cilium (green) in hfNBMs (DAPI counterstained nuclei, scale bar 10 µm). The number of ciliated cells was counted in 10 different random fields and expressed as
percentage of DAPI-stained total cells; data are mean ± SEM of three separate experiments (◦◦p < 0.001 vs. CTL, ##p < 0.001 vs. NGF). (H) Immunoblotting of
ChAT expression in cells treated or not with 10–100 ng/ml NGF for 24 h in presence or absence of 200 nM K252a; band intensity was normalized over β actin signal
and expressed as % of control; data are mean ± SEM (∗p < 0.05, ∗∗p < 0.01 vs. CTL; #p < 0.05 vs. respective NGF; n = 3).
methoctramine, a muscarinic receptor antagonists that binds
to M2 with high affinity. [3H]-NMS binding was completely
inhibited by methoctramine providing evidence that M2 is
expressed in these cells (Supplementary Figure S2B). The
competition-binding assays performed with methoctramine
yielded displacement curves, best described with a two-site
binding model (pKiH = 8.18 ± 0.37; pKiL = 6.21 ± 0.21; n = 3;
p< 0.01; Supplementary Figure S2B).
NGF Activates a Functional TrkA Signaling
Pathway in hfNBMs
Experimental evidence indicates that NGF/TrkA signaling
supports survival, maintenance, connectivity and function of
the brain cholinergic neurons. As we demonstrated that
hfNBMs express the TrkA receptor (Figures 1C,E), we next
questioned whether the formation of a NGF-TrkA complex
activated a functional TrkA signaling pathway and assessed
the phosphorylation of TrkA (pTrkA) and the activation of
TrkA down-stream effectors (p-ERK1/2, p-CREB or c-fos). After
24 h of serum starvation, cells were stimulated with 100 ng/ml
NGF and then harvested at different time points. Western blot
analysis with specific antibodies revealed that NGF significantly
induced pTrkA within 3′-15′ and p-ERK1/2 or p-CREB at
30’, whereas maximum activation of c-fos was within 3.5 h
(Figures 4A–D; p < 0.05). Preincubation with the specific
receptor inhibitor K252a prevented all these effects. To test the
role of NGF on hfNBMs proliferation, we treated cells with
two different concentrations of NGF (10 and 100 ng/ml) for
24 h. Using the colorimetric MTT assay we found the 100 ng/ml
NGF caused a significant increase in cell number (p < 0.005
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FIGURE 5 | Estrogen receptors expression and estrogen effects on hfNBMs. (A) Relative mRNA expression by qRT-PCR analysis of ERα, ERβ and GPR30 receptors
normalized over 18S ribosomal RNA subunit, taken as the reference gene, and reported as mean ± SEM (n = 6). (B–D) Immunocytochemical detection of ERα, ERβ
and GPR30 in hfNBMs (DAPI counterstained nuclei in (D), scale bar 50 µm). (E,F) MTT analysis of hfNBMs treated or not (CTL) with increasing concentrations of E2
(10−13–10−6 M) or the GPR30 agonist G1 (10−9–10−6 M) for 24 h in the presence or absence of the ERα/ERβ antagonist tamoxifen (TAM; 100 nM) or the
GPR30 antagonist G15 (1µM), respectively (∗p < 0.05, ∗∗p < 0.01, ◦◦p < 0.001 vs. CTL; #p < 0.05, ##p < 0.001 vs. treated cells; n = 3). (G) Neurite outgrowth
analysis by α-tubulin staining of hfNBMs treated with 10 nM E2 for 24 h in presence or absence of TAM (100 nM) or treated with 100 nM G1 for 24 h in presence or
absence of G15 (1 µM); the graph shows the percentage of cells with neurites longer than four times the cell body calculated by counting ten fields per slide of three
separate experiments (∗∗p < 0.01, ◦◦p < 0.001 vs. CTL; ##p < 0.001, ++p < 0.005 vs. treated cells; DAPI counterstained nuclei, scale bar 100 µm).
(H) Immunoblotting of ChAT expression in serum-starved cells treated or not (CTL) with increasing concentrations of E2 (0.1–100 nM) or with 1 nM E2 in the
presence of TAM (100 nM) alone or in combination with G15 (1 µM) for 24 h; band intensity was normalized over β actin signal and expressed in % of CTL; data are
mean ± SEM (∗p < 0.05, ∗∗p < 0.01, ◦◦p < 0.001, §§p < 0.005 vs. CTL; #p < 0.05 vs. E2 10 nM, n = 3).
vs. untreated cells), which was blocked by the addition of K252a
(Figure 4E; p< 0.005 vs. NGF). The effect of NGF on cholinergic
neuronal differentiation was determined by analyzing neurite
outgrowth. Serum-starved cells were incubated with 100 ng/ml
NGF for 24 and 48 h, and the occurrence of neurite elongation
was evaluated by immunofluorescent detection of α-tubulin, in
comparison with untreated cells (Figure 4F). Neurite outgrowth
was determined by measuring the ratio between the longest
neurite length and the cell body diameter and calculating the
percentage of cells with a particular ratio, as already described
(González-Martínez et al., 2004; Sarchielli et al., 2014). As shown
in Figure 4F, in the absence of treatments, about 15% of cells
(15.6 ± 2% at 24 h and 14.3 ± 3.4% at 48 h) showed neurites
longer than four times the cell body, while the percentage
was significantly increased after 100 ng/ml NGF treatment at
both 24 h (44.5 ± 3.2%, p < 0.001) and 48 h (62.8 ± 6.5%,
p< 0.001), an effect prevented by preincubating cells with K252a
at both time points. The effect of NGF on neuritogenesis was
confirmed by analyzing growth associated protein 43 (GAP43)
protein expression (Supplementary Figure S3). Interestingly,
acetylated α-tubulin immunostaining, which specifically detects
the formation of a primary cilium, revealed that NGF treatment
significantly increased the percentage of cells exhibiting this
organelle (34.8 ± 1.8%; Figure 4G), as compared to untreated
cells (17.3 ± 2.3%; p < 0.0001), an effect inhibited by K252a
(15.1 ± 3.2%). Because NGF is an essential regulator of
cholinergic neuronal phenotype, we also investigated whether
the neurotrophin could modulate ChAT expression. As shown
in Figure 4H, either 10 or 100 ng/ml NGF significantly
increased ChAT protein expression, compared with untreated
cells (p < 0.05 and p < 0.01, respectively), an effect blocked
by K252a.
Effects of Estrogen on hfNBMs
Based on the evidence in literature about the possible
association between estrogen plasma levels and AD incidence,
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FIGURE 6 | Effects of hfNBMs intravenous administration in nucleus basalis of Meynert (NBM)-lesioned rats. (A,B) Immunohistochemical detection (A) and
quantification (B) of ChAT positive cells in the right NBM of quisqualic acid (QA)-injected rats, compared to saline-injected rats; nuclei are counterstained with DAPI
(scale bar 50 µm). Data are expressed as percentage of ChAT-positive neurons (mean ± SEM), taking saline-injected rats as 100% (∗p < 0.001; n = 3 per group).
(C) Representative image showing incorporation of the red fluorescent dye PKH26 in hfNBM cells (DAPI counterstaining, scale bar 10 µm). (D) Localization of
PKH26-labeled hfNBM cells (red) and evaluation of astrogliosis (white arrows) by anti-GFAP staining (green) in the right NBM of QA-injected compared to
saline-injected rats (DAPI counterstaining, scale bar 10 µm). (E) Merge of dual labeling of ChAT (green) and the dye PKH26 (red) in NBM sections of QA-injected rats
at day 21 (scale bar 20 µm); ChAT is expressed in hfNBM cells as demonstrated by the yellow color. (F,G) Working memory assessment: (F) Morris water maze
(MWM) test, QA-injected rats required significantly more time to find the platform at day 2 and 3 (∗p < 0.05, ∗∗∗p < 0.001, respectively) compared to controls, while
the QA + hfNBMs group showed a response similar to controls and significantly different from QA rats (◦p < 0.05 day 2 and ◦◦p < 0.01 day 3; n = 5–6 per group);
(G) Step-down inhibitory avoidance test, the training test showed no significant differences between groups. The 24 h retention test showed increased latencies in
controls (∗∗p < 0.01) and QA+ hfNBMs rats (∗∗∗p < 0.001) vs. respective training latencies. In QA rats retention latencies were significantly reduced respect to
controls and QA+ hfNBMs (◦◦◦p < 0.001) and not significantly different from training latencies (n = 5–6 per group).
we next investigated whether hfNBMs expressed estrogen
receptors and responded to 17β-estradiol (E2). As shown
in Figure 5, mRNA expression analysis (Figure 5A) and
immunofluorescent detection (Figures 5B–D) demonstrated
that hfNBMs possessed both classical estrogen receptors
(ERα and ERβ), along with the transmembrane G protein-
coupled ER (GPR30/GPER1), which is known to mediate
rapid non-genomic actions. Increasing concentrations of E2
(0.1–100 nM) or G1 (1–1000 nM), a specific GPR30 agonist,
determined a dose-dependent increase in cell number after
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24 h exposure, which was reverted by the pre-treatment
with either the ERα/ERβ antagonist tamoxifen (100 nM) or
the selective GPR30 antagonist G15 (1 µM), respectively
(Figures 5E,F). Similar effects were observed in terms of
hfNBMs differentiation, since 24 h exposure to 10 nM E2 or
100 nM G1 significantly induced neuritogenesis, an effect
fully abolished by the respective antagonists tamoxifen or
G15 (Figure 5G; p < 0.05). In addition, E2 (0.1–100 nM,
24 h) determined a significant dose-dependent increase in
ChAT protein expression (p < 0.05 for each E2 concentration
vs. control), which tended to be reduced by tamoxifen pre-
treatment, although without reaching statistical significance
(Figure 5H). Pretreating cells with both G15 and tamoxifen
significantly counteracted E2 effect (Figure 5H), thus suggesting
a crucial involvement of GPR30 activation in inducing
estrogen-mediated ChAT expression. Accordingly, G1 fully
mimicked E2 effects on ChAT expression (Supplementary
Figure S4).
hfNBMs Improve Memory Functions in
NBM-Lesioned Rats
To test the ability of hfNBMs in improving injured cholinergic
function, we performed in vivo experiments using an acute
animal model of AD, generated by the unilateral injection
of quisqualic acid (QA) into the right NBM of adult
male rats. In accordance with previous report (Bartolini
et al., 1996), 21 days after NBM lesioning the number of
magnocellular ChAT-positive neurons in the QA-injected side
was significantly reduced (−64%) compared to saline-injected
NBM (Figures 6A,B, p < 0.001). Intravenous administration of
hfNBMs was performed in subgroups of QA- and saline-injected
rats. To evaluate whether the intravenously administered cells
reached the lesioned NBM, hfNBMs were labeled with the red
fluorescent dye PKH26 (Figure 6C). As shown in Figure 6D,
the immunohistochemical analysis of astrogliosis revealed the
presence of reactive GFAP-positive astrocytes with enlarged cell
bodies and long processes in NBM sections from QA- but
not saline-injected rats (Figure 6D). The presence of PKH26-
labeled hfNBMs was detected both in the QA- and saline-injected
NBM (Figure 6D). Immunofluorescent staining with ChAT
antibody of NBM sections from the experimental rats showed
that PKH26-labeled cells were ChAT-positive, as exemplified by
the merge image from QA-injected rats at day 21 (Figure 6E).
No PKH26-labeled cells were detected in uninjured brain areas,
including cortex, striatum, medial septum and peduncolopontine
nuclei of both cerebral hemispheres, nor in the left unlesioned
NBM.
The effects of hfNBMs administration on cognitive functions
were assessed with both MWM and step down inhibitory
avoidance tests. At day 21, rats from each experimental group
(n = 5–6 per group) were trained for 4 days in the MWM
task to learn where the hidden platform was located. The rats
were naive to the water maze and showed no deficiencies in
swimming abilities, directional swimming towards the platform,
or climbing onto a hidden platform during training trials. As
shown in Figure 6F, QA-injected rats required significantly more
time to find the platform compared to controls (p < 0.05, day 2,
and p < 0.001, day 3). Interestingly, rats from the QA-injected +
hfNBMs group were good swimmers and showed an appropriate
swim-search response after being placed in water, significantly
shortening the escape latency during the 2- and 3-day acquisition
phase compared to QA-injected group (Figure 6F; p < 0.05,
day 2 and p < 0.01, day 3). At day 4 of acquisition phase,
QA-injected rats shortened the escape latency with no significant
differences when compared to QA+ hfNBMs or control rats
(Figure 6F). No differences were detected in the escape latency in
all acquisition phase sessions between control and saline-injected
+ hfNBMs rats (data not shown). The same animals were then
tested for the step-down inhibitory avoidance (n = 5–6 per group;
Figure 6G). No significant differences were observed among
all groups during the training test. In the 24 h retention test
step-down latencies recorded for controls and QA+ hfNBMs
rats were significantly increased (p < 0.01 and p < 0.001 vs.
their respective training latencies). In QA rats retention latencies
were significantly reduced compared to controls and QA+
hfNBMs (p< 0.001) and not significantly different from training
latency, indicating that QA rats were unable to memorize
the punishment and to perform the inhibitory avoidance.
Administration of hfNBMs to QA rats significantly improved
their performance, which reached the level displayed by control
rats (Figure 6G). No differences were detected during retention
test between control and saline injected + hfNBMs rats (data not
shown).
DISCUSSION
The impairment of the BF cholinergic system, especially NBM,
is a crucial event in the progression of memory and cognitive
decline associated to neurodegenerative disorders, such as AD. It
therefore represents the main target for therapeutic approaches
(Ferreira-Vieira et al., 2016). The most efficient treatment should
be able to direct a regenerative process of the damaged brain
areas, a possibility currently under consideration in the attempt
to establish efficient stem cell-based replacement therapies for
AD. Studies on derivation of functional BF cholinergic neurons
from stem cells are limited (Bissonnette et al., 2011; Liu
et al., 2013; Yue et al., 2015) and, although the regenerative
potential has been proved in AD animal models, the actual
application in clinical protocols seems far to be reached. Besides
the generation of functionally integrated stem cell-derived
cholinergic neurons, major efforts should be directed towards
unraveling those mechanisms that may protect NBM neurons
from degenerative insults, with the main aim of identifying
efficient strategies to prevent AD pathogenesis. In this study,
we provide for the first time a comprehensive phenotypic
and functional characterization of primary human cholinergic
neurons isolated from the fetal NBM. They may represent not
only an optimal resource to study developmental processes
of neurons already committed towards the NBM cholinergic
phenotype, but also a useful model in the assessment of
regenerative protocols based on an efficient generation of stem
cell-derived NBM cholinergic neurons. Indeed, we show that
hfNBMs, without any manipulation and via systemic injection,
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were able to determine a functional recovery in NBM-lesioned
rat brain.
The hfNBM primary cultures clearly showed a prominent
neuronal phenotype, with high levels of MAP2 transcripts,
which was confirmed by the flow cytometry detection of
almost 100% of MAP2-positive cells. In addition, hfNBMs
abundantly express both the neural precursor marker nestin
and the neuronal progenitor marker β tubulin III, indicating
coexisting undifferentiated cells already committed towards a
specific phenotype. This plasticity was expected in primary
cultures of fetal origin (Sarchielli et al., 2014) and may be
of great value to study mechanisms potentially interfering
with cholinergic neuron maturation and function. The hfNBM
identity as cholinergic neurons was demonstrated by the
expression of the major components of the cholinergic system,
including proteins important for Ach synthesis, transport and
hydrolysis (ChAT, VAchT and AchE, respectively). Accordingly,
a basal release of Ach by these cells has been detected.
In addition, the hfNBM neurons express CALB1 along with
both high- (TrkA) and low- (p75/CD271) affinity NGF
receptors, which altogether define the regional specificity
of NBM cholinergic neurons (Abreu-Villaça et al., 2011).
Indeed, in humans all the BF cholinergic neurons were
also CALB1-positive (Geula et al., 1993) and co-expression
of CALB1 with both NGF receptors is consistent with the
pattern described for the Ch4 neurons of the human brain,
which correspond to NBM according to the Mesulam’s
nomenclature (Mesulam, 2013). Although, we might expect to
also isolate GABAergic and glutamatergic neurons from the
BF, in our primary cultures the majority of cells, as detected
by flow cytometry, were ChAT-positive (97%). Our findings
are in accordance with previous immunocytochemical and
hybridization studies (Mufson et al., 2003) reporting a high
enrichment of cholinergic neurons (90%) within the human
NBM/Ch4 region.
The functional validation of the neuronal profile of hfNBM
cells was provided by electrophysiological measurements, which
demonstrated the presence of a polarized membrane potential
(∼−45 mV), the expression of functional, TTX-sensitive,
voltage-gated Na+ channels (INa), along with the presence of
active phenomena of firing activity, in line with previous data
on human developing neuronal cells (Lepski et al., 2011; Song
et al., 2013). Furthermore, we detected transient IA currents,
delayed rectifier IK and inwardly rectifying Kir currents. The
presence of IA and IK currents has been previously detected in
human fetal brain neurons (Sah, 1995). In our population of
isolated hfNBM neurons, IK were the predominant conductance
recorded in all cells tested and INa currents were present in
the vast majority (89%) of hfNBMs. Transient IA currents
and Kir conductances were only detected in a subset of
recorded cells (37% and 41%, respectively), suggesting that
hfNBMs culture might include a heterogeneous population of
neurons at different maturation steps or with distinct arrays
of K+ channels. Interestingly, hfNBMs also exhibited the
presence of functional cholinergic receptors. Ach binds to two
distinct types of receptors: ionotropic nicotinic (nAchR) and
metabotropic muscarinic (mAchR) receptors, located in both
pre- and post-synaptic membranes of neurons. In particular,
nAchR are pentameric ligand-gated ion channels resulting
from the combination of different α (α2–10) and β (β2–4)
subunits (Gotti et al., 2007). We demonstrated not only that
hfNBM cells expressed, at mRNA level, all nAchR subunits
investigated, with the α5 subunit being the most abundant,
but also that they were able to respond to nicotine by
triggering a 0 mV-reverting ramp-evoked current and membrane
depolarization. Our results are consistent with the early detection
of nAChR proteins and gene transcripts in brains from human
fetuses of 4–12 weeks of gestational age (Hellström-Lindahl
et al., 1998). They also further support the important role
proposed for nAchRs during brain development in modulating
dendritic outgrowth, establishment of neuronal connections and
synaptogenesis (Abreu-Villaça et al., 2011). Future investigations
aimed at identifying the specific subunits assembly of nAchRs,
which are active in hfNBMs in the different maturation
states, will help to clarify the neurodevelopmental actions of
Ach. The relative abundancy of the α5 subunit in hfNBMs
may suggest the importance of this subunit in regulating
the nAchRs activity during cholinergic neuron development.
Indeed, among nAchRs subunits, the α5 plays a peculiar
functional role, since it contributes to the lining of functionally
unique nAchR channels, but only if co-expressed with both
another alpha- and beta-type subunit (Ramirez-Latorre et al.,
1996). Moreover, studies in animal models have shown that
ubiquitously distributed presynaptic nAchRs serve as ligand-
gated ion channels that promote neurotransmitter release
(Wonnacott et al., 2006). Hence, further studies should be
addressed to clarify if nAchRs in our cellular model of cholinergic
neurons could play a role as presynaptic receptors recruited to
regulate Ach release.
We also clearly show that Ach activates mAchRs receptors
in hfNBMs. Five subtypes of mAchRs have been described
(M1–M5) with an inhibitory (M2 and M4) or excitatory
(M1, M3 and M5) action on neuronal excitability (Caulfield,
1993). M2 and M3 subtypes resulted the most abundant in
hfNBMs. Again, our results are consistent with literature data
highlighting the importance of mAchRs, like nAchRs, in the
developing central nervous system linked to clear effects of
Ach on neuronal proliferation, differentiation and survival
(Abreu-Villaça et al., 2011). Moreover, the presence of abundant
M2 transcripts along with specific M2-type binding sites may
reflect a prominent regulatory role of mAchRs as autoreceptors
on Ach release in hfNBM cells. In line with this observation, we
describe an ATR-sensitive increase in delayed rectifier outward
IK currents upon Ach or Cch application, as known for Gi
coupled metabotropic receptors such as M2 and M4 subtypes
(Caulfield and Birdsall, 1998). This effect could be either due to
a direct action of the G protein subunit/s on K+ channels, or
by second messenger-mediated (i.e., cAMP-mediated) channel
modulation, as both possibilities have been described in other
cellular systems (Inanobe and Kurachi, 2014). Since either Ach
or Cch effects on IK currents peaked within only 1–2 min
from agonist superfusion, we may hypothesize a direct action
of the Gα or Gβ/γ subunit/s coupled to muscarinic receptor
activation on delayed rectifier K+ channels. Overall, it emerges
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from present data that nicotinic receptors excite hfNBMs
by depolarizing the cell membrane and approaching them
to firing threshold, whereas mAchR activation, by opening
IK channels, could result inhibitory on neuronal excitability.
However, given the fetal origin of our cellular model, the
specific recruitment of either nicotinic or muscarinic receptor
subtypes could be related to maturation processes of the
cholinergic phenotype induced by Ach, as reported (Bruel-
Jungerman et al., 2011), rather than to specific functional
responses, such as those occurring in the context of adult
brain circuits. This issue merits further investigations in future
studies.
Several lines of evidence indicate that NGF is an endogenous
neurotrophic factor crucially required to support survival,
maintenance, connectivity and function of the brain cholinergic
neurons, as derived by extensive research involving a wide
range of animal models (Dekker et al., 1991; Koliatsos et al.,
1991). Consistently with these findings, we demonstrated that
NGF induces, via TrkA activation and its downstream signaling
pathways, proliferation, neuritogenesis and ChAT expression in
hfNBMs, thus confirming also in a human model the role played
by the neurotrophin in the development and maintenance of
the cholinergic phenotype. Accordingly, phase 1 clinical trials
based on NGF gene delivery to NBM proved that this approach
has the potential to improve cognitive symptoms and modify
neurological disease progression in AD patients (Tuszynski et al.,
2005). Interestingly, among the effects observed upon NGF
treatment, the increased percentage of hfNBMs exhibiting a
primary cilium appears of particular interest given the recent
involvement of this organelle in the adult neurogenesis (Han
et al., 2008). Primary cilia are non-motile, 4–8 µm long sensory
antennas protruding from the surface of nearly all cells of
the body, able to mediate the cellular response to extracellular
signals growth and other factors (Armato et al., 2013). In
particular, primary cilia have been detected in adult murine
and rat neural stem/progenitor cells of the dentate gyrus’s
subgranular zone (SGZ), which may produce new granule cells
when they are needed for new memory encoding (Einstein et al.,
2010). Accordingly, primary cilia of SGZ cells showed structural
damages in transgenic AD mouse models (Rodríguez et al.,
2008). Nevertheless, the precise role that primary cilia play in the
overall neuronal function is still unknown. Our results strongly
suggest for the first time that primary cilia may be involved
in the NGF-driven maturation of human NBM cholinergic
neurons. Further investigations may clarify the effective role
of the primary cilium in the signaling mechanisms directly or
indirectly recruited by NGF in the overall neuronal maturation.
Since most evidence suggested that primary cilia signaling is
based on an enrichment of receptors on its membrane (Händel
et al., 1999), it would be interesting to analyze whether NGF
receptors co-localize to primary cilia of hfNBMs. In this regard,
the p75 low-affinity NGF receptor has been found in adult
murine hippocampal dentate gyrus granule cells (Chakravarthy
et al., 2010) and showed to be involved in the amyloid β42 toxic
activity (Perini et al., 2002).
Accumulating evidence in animal models indicated that
various neuronal functions, including learning and memory
processes, are beneficially influenced by estrogens (Engler-
Chiurazzi et al., 2016). Accordingly, in humans, it has been
reported that the risk of AD is higher for women than
men, especially in post-menopausal women compared to their
male counterpart, clearly suggesting a neuroprotective role of
estrogens (Breitner et al., 1988; Jorm and Jolley, 1998). Indeed, a
recent meta-analysis of modifiable risk factors for AD identified
the use of estrogens among the protective factors (Xu et al., 2015).
Although controversial literature exists about the effectiveness
of estrogen replacement therapy in preventing AD, several
animal studies have shown that estrogens are neuroprotective
for multiple targets in the central nervous system, including
hippocampal neurogenesis and BF cholinergic neuron survival
and function (Engler-Chiurazzi et al., 2016). In this regard, we
report that hfNBMs express estrogen receptors. In particular,
besides the classical nuclear ERα and ERβ, hfNBM cells also
express the membrane-associated GPR30, a G protein-coupled
receptor responsible for the rapid non-genomic actions of
estrogens (Revankar et al., 2005). The most striking finding of
our study is that the different types of estrogen receptors could
be differently involved in mediating estrogenic action on growth,
differentiation and maintaining of cholinergic phenotype in
hfNBMs. Indeed, exposing cells to E2 induced cell proliferation,
neuritogenesis and ChAT expression, with all effects mimicked
by the exposure to G1, the selective GPR30 agonist, clearly
implying the recruitment of rapid non-genomic mechanisms.
However, pre-treatment with tamoxifen (an effective ERα and
ERβ antagonist) counteracted all the estrogen-induced changes
in hfNBMs, except for ChAT protein expression increase that
was significantly prevented only in the presence of the specific
GPR30 antagonist G15. Hence, GPR30 appears to be crucially
required for the estrogenic action on maintenance of cholinergic
phenotype in hfNBMs. Our findings are in good agreement
with the recent evidences in experimental animals, which
revealed that GPR30 is positioned on BF cholinergic neurons to
mediate important estrogenic actions, such as effects on cognitive
performance (Hammond and Gibbs, 2011) and Ach release in the
hippocampus (Gibbs et al., 2014). A better understanding of the
precise molecular mechanisms through which GPR30 regulates
memory and cognition in humans will help to the development
of more effective therapies for preventing and treating cognitive
decline associated with AD.
Another important finding of our study is the demonstration
that hfNBMs were able to improve cognitive functions when
administered to a rat model of AD, obtained via the unilateral
lesion of NBM. In particular, hfNBMs administration in
NBM-lesioned rats determined a significant recovery of memory
deficits. Memory is the product of dynamic interactions among
multiple systems in the brain. Notably, working and spatial
memory for the platform location appears to be mainly
hippocampus-dependent as this brain area, which receives
cholinergic inputs from the BF nuclei, is necessary for acquisition
and retrieval of spatial information. Indeed, lesions of the
medial septal and diagonal band cholinergic neurons result in
deficits in the MWM task (Janis et al., 1998). However, memory
performance in MWM is also affected by the NBM neuron
activity resulting NBM lesion and stimulation in deficits and
Frontiers in Cellular Neuroscience | www.frontiersin.org 14 October 2017 | Volume 11 | Article 339
Morelli et al. Human Basal Forebrain Cholinergic Neurons
improvements, respectively, in the acquisition of spatial memory
tasks (Lee et al., 2016). The step-down inhibitory avoidance
memory depends mainly on the integrated activity of entorhinal,
parietal cortex and CAI areas. Hence, lesions of the NBM,
which provides the major cholinergic innervation to the entire
cortical mantle, are mainly responsible for memory deficits in
this task (Torres et al., 1994; Giovannini et al., 2015; Lee et al.,
2016). Accordingly, our findings showing that spatial memory
impairments in the MWM test of untreated NBM-lesioned
animals recovered after 3 days of training indicate that NBM does
not play a primary role in the acquisition of spatial memory task
and that other cellular and molecular mechanisms underlie the
spontaneous and hfNBM-induced spatial memory restoration. In
contrast, memory deficits in the step-down inhibitory avoidance
test of untreated NBM-lesioned animals persisted during the
entire test, indicating that the memory disturbance in this task
mainly reflects NBM activity.
We did not specifically analyze whether neuronal connections
between donor and host neurons occurred, as well as no data
about an improvement of cholinergic activity (Ach secretion)
in brains from QA-lesioned/hfNBM-treated compared to QA-
lesioned/untreated rats are provided. However, based on both
the in vitro functional characterization and in vivo results, it
is plausible that hfNBMs, at least for 3 weeks, retained their
phenotype able to exert a trophic activity on the host injured
cholinergic area. In addition, the fact that hfNBMs, intravenous
administered, were detected in the NBM injected either with
QA or saline and not in other brain areas not interested by
the insult indicates that a damage of the blood brain barrier
favors the migration of cells to injured brain sites. Although
the manner in which injected neurons systemically reach the
damaged brain area remains unknown, similar studies in models
of neurodegenerative diseases demonstrated that intravenous
route for stem cell transplantation is feasible and effective
(Lee et al., 2005; Shen et al., 2010; Martínez-Morales et al.,
2013). Most likely, the ability of migrating and penetrating
to a specific site, as well as recapitulating specific functions,
is related to an already committed phenotype and may be
ascribed to the fetal origin of our cellular model, thus supporting
the validity of such a model for cell-based therapy purposes.
Indeed, as occurred for the assessment of cell-based therapy
protocols for the treatment of PD (Grealish et al., 2014),
human fetal neurons may serve as an important reference in
terms of morphology, maturation, marker expression and overall
phenotypic properties.
In conclusion, this study is the first in which human NBM
cholinergic neurons are isolated and fully characterized and
where their potential role for functional repair, without any
manipulation, has been tested in vivo in an experimental model
of AD. Such a model of young neurons, clearly programmed
to the cholinergic function, possesses functional channels and
receptors able to respond to important physiological regulators
(Ach, NGF, estrogens). It therefore represents an excellent
tool to study the ontogenetic mechanisms regulating the
development and maintenance of the human BF cholinergic
system. In addition, this cellular model could be useful to assess
new lines of research including disease modeling, cell-based
therapy and drug screening in the field of neurodegenerative
disorders.
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